Task Force on Clinical guideline on reversal of direct oral anticoagulants in patients with life threatening bleeding

Task Force on Clinical guideline on reversal of direct oral anticoagulants in patients with life threatening bleeding

Several direct oral anticoagulants (DOACs), including direct thrombin and factor Xa inhibitors, have been approved as alternatives to vitamin K antagonist anticoagulants. In patients with major bleeding or needing urgent surgery, reversal of DOAC anticoagulation may be required, presenting a clinical challenge. Based on clinical evidence a task force on "Clinical guideline on reversal of direct oral anticoagulants in patients with life threatening bleeding" has been set up to publish recommendations for the use of specific antidotes and non-specific haemostatic interventions in the perioperative context including severe bleeding. This guideline will also review the use of laboratory measurements to monitor and guide perioperative management and haemostatic therapy for patients on DOACs.

Composition

Chairperson



Oliver Grottke

Members

Christian Fenger-Eriksen
Christian Von Heymann
Aamer Ahmed
Eleni Arnaoutoglou
Daniel Bolliger

If you have any question, please do not hesitate to contact us: guidelines@esaic.org